[의학신문·일간보사=김영주 기자]Within the area of exterior development within the first quarter of 2024, it was analyzed that the phenomenon of ‘the wealthy getting richer and the poor getting poorer’ among the many finest pharmaceutical firms is obvious, and the progress and setbacks by way of key merchandise due varied. circumstances that induced the distinction. Whereas the power of indigenous new medication (together with improved new medication and mixture of latest medication) and the weak point of launched originals remained, the change in huge field shops was inflicting combined feelings amongst firms. The expansion of things imported and made into merchandise by means of inner manufacturing, even when they weren’t self-developed merchandise, was additionally evident.
The gross sales standing of the principle merchandise of pharmaceutical firms for the primary quarter of 2024, ending in December
The day by day newspaper and the medical newspaper compiled the gross sales standing of key merchandise within the first quarter of 2024 for 65 listed pharmaceutical firms in December and Hyundai Prescribed drugs in November. This depend coated merchandise with annual gross sales of greater than 10 billion items between 2022 and 2023, and merchandise from pharmaceutical firms similar to GC Pharma that didn’t publish the gross sales efficiency of particular person merchandise weren’t excluded.
On this account, the efficiency of final 12 months and the earlier 12 months was revealed, and the merchandise that recorded gross sales of greater than KRW 10 billion over the 2 years had been 154 pharmaceutical objects from 18 firms, and the entire gross sales of these things within the first this 12 months’s quarter was KRW 1.6528 trillion, a development of 5.92% over the earlier 12 months. 90 objects grew, and 64 objects confirmed unfavourable development. The expansion charge of 5.92% for key merchandise was nearly equivalent to the general pharmaceutical gross sales development charge of 5.94%.
Among the many predominant merchandise introduced by every firm on this account, a complete of 177 objects may have gross sales of greater than 10 billion gained in 2022 and 2023. Final 12 months there have been solely 157 objects, this 12 months there have been 20 objects. While you have a look at the principle pharmaceutical merchandise, you may see the corporate’s current and future.
In Korea, merchandise with annual gross sales of greater than 10 billion gained are acknowledged as blockbuster merchandise, and an rising variety of flagship merchandise issued by an organization signifies that they’re at the moment doing properly and that they’ve vibrant prospects. However, if the introduced merchandise are restricted to current merchandise and the corporate continues to take steps again, it displays that the corporate is in disaster.
The truth that the variety of key merchandise has elevated on this account is proof that pharmaceutical firms have promising prospects for the long run.
From the start of this 12 months, the power of home new medication was evident. Daewoong Pharmaceutical’s P-CAB Collection Gastroesophageal reflux illness remedy Fexuclu grew 56.03% in gross sales to KRW 18.2 billion within the first quarter, and Hanmi Pharmaceutical’s dyslipidemia remedy advanced new drug Rosuzet elevated 17.83% to KRW 48.9 billion.
Boryung Kanarb Household’s new hypertension drug grew 15.54% with gross sales of KRW 38 billion, and HK Innoen’s P-CAB sequence gastroesophageal reflux illness remedy Okay-Cap grew 113.87% with gross sales of KRW 51.8 billion. As well as, Dong-A ST Grotropin’s development hormone product additionally elevated by 15.07% to KRW 26.6 billion.
Particularly, Okay-Cap’s greater than two-fold development is attracting consideration, and gross sales elevated considerably by altering from gross sales by means of collaboration with Chong Kun Dang to unique gross sales till final 12 months.
After that, a joint sale settlement with Boryeong is anticipated, so the state of affairs is anticipated to vary. From Chong Kun Dang’s viewpoint, gross sales development was troublesome as a result of sudden absence of things competing for first or second place in gross sales, however with the joint sale of Pexuclu with Daewoong Pharmaceutical, a member of the identical household P- CAB, the way forward for developments out there attracts consideration.
One other facet that’s notable on this account is the power of the objects introduced which have truly been made into their very own merchandise by means of copyright acquisition and in-house manufacturing.
JW Pharmaceutical’s new drug for dyslipidemia, Livaro, is an launched product, however it’s truly a home-produced product with the addition of a brand new home-manufactured drug, enhanced and compounded. It grew 12.93% with gross sales of KRW 38.4 billion within the first quarter of this 12 months.
Boryeong’s distinctive LBA technique merchandise additionally confirmed a speedy development development. LBA is a technique to amass authentic medication that may preserve a excessive market share even after patent expiration.
These objects, Zyprexa, a schizophrenia remedy, grew 101.35% with gross sales of KRW 7.4 billion, Alimta, a non-small cell lung most cancers remedy, grew 10.51% with gross sales of KRW 5.3 billion, and Gemza, an anticancer drug, grew 29.03% with gross sales KRW 4.7 billion.
The outstanding development of Kwangdong Pharmaceutical (249.6 billion gained in gross sales, a development of 16.51%) additionally attracted consideration, and the human papilloma virus (HPV) vaccine ‘Gardasil’ (31.7 billion gained in gross sales), which has been launched and’ to promote beginning this 12 months, is one huge enhance.
#Home #medication #sturdy #begin #12 months
